Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Brain Metastasis Center, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
J Neurooncol. 2022 Sep;159(3):609-618. doi: 10.1007/s11060-022-04101-9. Epub 2022 Jul 27.
Salvage of recurrent previously irradiated brain metastases (rBrM) is a significant challenge. Resection without adjuvant re-irradiation is associated with a high local failure rate, while reirradiation only partially reduces failure but is associated with greater radiation necrosis risk. Salvage resection plus Cs131 brachytherapy may offer dosimetric and biologic advantages including improved local control versus observation, with reduced normal brain dose versus re-irradiation, however data are limited.
A prospective registry of consecutive patients with post-stereotactic radiosurgery (SRS) rBrM undergoing resection plus implantation of collagen-matrix embedded Cs131 seeds (GammaTile, GT Medical Technologies) prescribed to 60 Gy at 5 mm from the cavity was analyzed.
Twenty patients underwent 24 operations with Cs131 implantation in 25 tumor cavities. Median maximum preoperative diameter was 3.0 cm (range 1.1-6.3). Gross- or near-total resection was achieved in 80% of lesions. A median of 16 Cs131 seeds (range 6-30), with a median air-kerma strength of 3.5 U/seed were implanted. There was one postoperative wound dehiscence. With median follow-up of 1.6 years for survivors, two tumors recurred (one in-field, one marginal) resulting in 8.4% 1-year progression incidence (95%CI = 0.0-19.9). Radiographic seed settling was identified in 7/25 cavities (28%) 1.9-11.7 months post-implantation, with 1 case of distant migration (4%), without clinical sequelae. There were 8 cases of radiation necrosis, of which 4 were symptomatic.
With > 1.5 years of follow-up, intraoperative brachytherapy with commercially available Cs131 implants was associated with favorable local control and toxicity profiles. Weak correlation between preoperative tumor geometry and implanted tiles highlights a need to optimize planning criteria.
复发性既往放疗后脑转移瘤(rBrM)的挽救是一个重大挑战。不进行辅助再放疗的切除术与高局部失败率相关,而仅再放疗部分降低失败率,但与更大的放射性坏死风险相关。挽救性切除术加 Cs131 近距离放疗可能具有剂量学和生物学优势,包括与观察相比改善局部控制,与再放疗相比降低正常脑剂量,但数据有限。
对连续接受立体定向放射外科(SRS)后 rBrM 切除术加胶原基质嵌入 Cs131 种子(GammaTile,GT Medical Technologies)植入的患者进行前瞻性登记,该种子在距腔 5 毫米处以 60Gy 处方。
20 例患者接受了 24 例手术,在 25 个肿瘤腔中植入了 Cs131。术前最大直径中位数为 3.0cm(范围 1.1-6.3)。80%的病变实现了大体或近全切除。中位数植入 16 颗 Cs131 种子(范围 6-30),每颗种子的空气比释动能中位数为 3.5U/颗。有一例术后伤口裂开。在幸存者的中位随访 1.6 年后,有 2 个肿瘤复发(1 个在野,1 个在边缘),导致 1 年进展发生率为 8.4%(95%CI=0.0-19.9)。在植入后 1.9-11.7 个月,7/25 个腔(28%)发现放射性种子沉降,1 例发生远处迁移(4%),无临床后遗症。有 8 例放射性坏死,其中 4 例有症状。
在随访时间超过 1.5 年的情况下,术中使用市售 Cs131 植入物进行近距离放疗与良好的局部控制和毒性特征相关。术前肿瘤几何形状与植入瓦片之间的弱相关性突出了需要优化规划标准的必要性。